General MedicationsINJECTIONStandard
IMFINZI
DURVALUMAB
Standard Dose
50MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview IMFINZI is listed in Drugs@FDA under application 761069 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient DURVALUMAB Form and strength INJECTABLE;INJECTION - 50MG/ML Sponsor ASTRAZENECA UK LTD Submission history Latest submission status date: 2025-11-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview IMFINZI is listed in Drugs@FDA under application 761069 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient DURVALUMAB Form and strength INJECTABLE;INJECTION - 50MG/ML Sponsor ASTRAZENECA UK LTD Submission history Latest submission status date: 2025-11-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.